ALEKSEY ARONOV: Open Payments
NPI 1548616451 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,241 in 48 payments from 14 companies in 2025. Trend: 2023 $2,226 · 2024 $1,242 · 2025 $1,241
Food & beverage: $1,241
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $222 |
| Celgene Corporation | 8 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $209 |
| GlaxoSmithKline, LLC. | 5 | $115 |
| Blueprint Medicines Corporation | 3 | $104 |
| Kite Pharma, Inc. | 5 | $100 |
| GENZYME CORPORATION | 3 | $89 |
| Rigel Pharmaceuticals, Inc. | 2 | $57 |
| Merck Sharp & Dohme LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $28 |
Products named: SCEMBLIX, REBLOZYL, AYVAKIT, ICLUSIG, OJJAARA, Yescarta, NINLARO, TAVALISSE.
Industry payments across NY — which companies pay providers there.
